1. Home
  2. RPD vs WVE Comparison

RPD vs WVE Comparison

Compare RPD & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPD
  • WVE
  • Stock Information
  • Founded
  • RPD 2000
  • WVE 2012
  • Country
  • RPD United States
  • WVE Singapore
  • Employees
  • RPD N/A
  • WVE N/A
  • Industry
  • RPD Computer Software: Prepackaged Software
  • WVE Biotechnology: Pharmaceutical Preparations
  • Sector
  • RPD Technology
  • WVE Health Care
  • Exchange
  • RPD Nasdaq
  • WVE Nasdaq
  • Market Cap
  • RPD 2.4B
  • WVE 2.1B
  • IPO Year
  • RPD 2015
  • WVE 2015
  • Fundamental
  • Price
  • RPD $38.84
  • WVE $10.99
  • Analyst Decision
  • RPD Buy
  • WVE Strong Buy
  • Analyst Count
  • RPD 18
  • WVE 10
  • Target Price
  • RPD $44.71
  • WVE $21.60
  • AVG Volume (30 Days)
  • RPD 671.1K
  • WVE 1.0M
  • Earning Date
  • RPD 02-12-2025
  • WVE 03-05-2025
  • Dividend Yield
  • RPD N/A
  • WVE N/A
  • EPS Growth
  • RPD N/A
  • WVE N/A
  • EPS
  • RPD 0.66
  • WVE N/A
  • Revenue
  • RPD $833,014,000.00
  • WVE $53,610,000.00
  • Revenue This Year
  • RPD $9.10
  • WVE N/A
  • Revenue Next Year
  • RPD $5.35
  • WVE $48.58
  • P/E Ratio
  • RPD $59.12
  • WVE N/A
  • Revenue Growth
  • RPD 10.05
  • WVE N/A
  • 52 Week Low
  • RPD $32.95
  • WVE $3.50
  • 52 Week High
  • RPD $61.88
  • WVE $16.74
  • Technical
  • Relative Strength Index (RSI)
  • RPD 42.30
  • WVE 34.06
  • Support Level
  • RPD $37.57
  • WVE $10.57
  • Resistance Level
  • RPD $40.42
  • WVE $12.03
  • Average True Range (ATR)
  • RPD 1.20
  • WVE 0.69
  • MACD
  • RPD 0.00
  • WVE -0.17
  • Stochastic Oscillator
  • RPD 33.33
  • WVE 12.54

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: